

Pulmonary Arterial Hypertension (PAH) Agents

Please provide the information below, please print your answer, attach supporting documentation, sign, date, and return to our office as soon as possible to expedite this request. Please FAX responses to: (800) 869-7791. Phone: (855) 322-4082, Options 0,1,2,3

Date of request:						
Patient	Date of birth		Molina ID			
Pharmacy name	Pharmacy NPI	Telep	hone number	Fax number		
Prescriber	Prescriber NPI	Telephone number Fax number				
Medication and strength		Dir	ections for use Qty/Days supply			
1. Is this request for a continuation of existing therapy? Yes No If yes, is there documentation supporting disease stability Yes No 2. Indicate the diagnosis: Pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group 1 and WHO Functional class II symptoms WHO Functional class III symptoms WHO Functional class IV symptoms Persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO group 3 or 4) Other. Specify No If not, was it due to one of the following: A contraindication to a calcium channel blocker Patient had a negative response to acute vasoreactivity test (AVT). Acute vasoreactivity test not indicated for the patient.						
	H functional class IV		cated (SBP < 90 r	mmHg; cardiac index < 2		
 4. Will the requested therapy be used in combination with any of the following (check all that apply)? Combination of phosphodiesterase inhibitor and soluble guanylate cyclase stimulator Combination of selexipag and parenteral prostanoid None of the above 						
 For Selexipag: Does the patient have a history of failure, contraindication, or intolerance to an endothelin receptor antagonist? Yes No 						

6. Is this prescribed by or in consultation with a specialist in one of the following:					
☐ Cardiology		Other. Specify			
CHART NOTES ARE REQUIRED WITH THIS REQUEST					
Prescriber signature	Prescriber specialty	Date			